Pharma Business - June 1, 2023
ProPharma announces new office in Medicon Village
ProPharma announces new office located in Ideon Science Park, effective on June 1, 2023. Ideon Science Park provides abundant opportunities and accessibility for individuals in the Öresund region, encompassing Lund, Malmö, and Copenhagen, describes the company. As members of the Medicon Village Alliance, ProPharma colleagues will have the advantage of actively engaging in events, meetings, […]
Biotech Business - May 30, 2023
Oculis listed on Nasdaq in New York
The Iceland-founded biopharmaceutical company was officially listed on the Nasdaq stock exchange in New York, making it the first Icelandic VC portfolio company to go public. Both Klappir and Solid Clouds were previously listed on the Nasdaq First North Growth Market in Iceland, but neither counted Icelandic VC’s as investors when going public. The same […]
Pharma Business - May 30, 2023
Novo Nordisk’s Sogroya receives CHMP positive opinion
Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending once-weekly Sogroya (somapacitan) for replacement of endogenous growth hormone (GH) in children aged three years and above, and adolescents with growth failure due to growth hormone deficiency. “Today’s positive CHMP opinion […]
Biotech Business - May 29, 2023
Alligator Bioscience receives FDA Orphan Drug Designation
The U.S. Food and Drug Administration has granted Orphan Drug Designation (ODD) to the company’s lead asset mitazalimab for the treatment of pancreatic cancer. “This designation is a key milestone for our lead asset mitazalimab, which is producing outstanding clinical results in its Phase 2 trial in pancreatic cancer,” says Søren Bregenholt, CEO of Alligator […]
Biotech Business - May 24, 2023
New Swedish innovation cluster for advanced therapies
On behalf of the Swedish government, the Swedish innovation agency Vinnova has decided on funding of an innovation cluster for commercialization, competence development and production capacity for advanced therapies. The new cluster will serve as a national infrastructure and competence node for the benefit of companies throughout the country and it will also strengthen Sweden’s […]
Agreement - May 24, 2023
Novo Nordisk collaborates with Edit Therapeutics
The two companies have announced a research and development collaboration to discover and develop gene editing therapies against a select set of therapeutic targets. With a focus on advancing base editing capabilities, Novo Nordisk will leverage Life Edit’s suite of gene editing technologies to precisely edit the genome with the aim of developing life-changing therapies […]
